Dr. Figlin Describes the Efficacy of AGS-003 in mRCC

Robert Figlin, MD, FACP, discusses updated data on the ADAPT trial, which is an ongoing international phase III randomized trial of autologous dendritic cell immunotherapy (AGS-003) plus standard treatment in metastatic renal cell carcinoma (mRCC)

Robert Figlin, MD, FACP, Professor of Medicine and Biomedical Sciences, Steven Spielberg Family Chair in Hematology Oncology, Cedars-Sinai Medical Center, discusses results from a single-arm phase II trial of the autologous dendritic cell immunotherapy AGS-003 plus standard treatment for patients with newly diagnosed metastatic renal cell carcinoma (mRCC).

In the trial, patients with mRCC received AGS-003 combined with sunitinib, Figlin says. The updated results show impressive survival findings, including a doubling in progression-free survival and an improvement in overall survival, for patients in the trial compared with a cohort of similar patients that were matched from other trials.

These impressive results set the stage for the ongoing randomized phase III ADAPT trial. Given the promising results from the phase II trial, Figlin is optimistic that AGS-003 should be able to demonstrate that a personalized vaccine in combination with sunitinib can enhance outcomes for patients with newly diagnosed mRCC, Figlin believes.


View more from the 2014 GU Cancers Symposium